Silexion Therapeutics LTD is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi)-based therapies and their delivery systems, specifically targeting aggressive solid tumors. The firm utilizes its proprietary LODER delivery platform for the treatment of these malignant growths. Its pipeline features SiG12D-LODER, which has successfully completed preclinical investigations and an open-label Phase I clinical trial for pancreatic cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$21.20 | -$5.17 | Beat |
| May 18, 2026 | -$12.90 | -$8.50 | Beat |
| Mar 17, 2026 | -$11.20 | -$23.85 | Miss |
| Nov 12, 2025 | -$34.00 | -$28.80 | Beat |
| Aug 12, 2025 | -$31.50 | -$43.20 | Miss |
| May 13, 2025 | -$33.00 | -$39.00 | Miss |